HOME >> BIOLOGY >> NEWS
Revealed: How a master protein remodels chromosomes to orchestrate gene expression

A team led by Terumi Kohwi-Shigematsu of Lawrence Berkeley National Laboratory's Life Sciences Division has demonstrated that SATB1, a protein crucial to the development of the immune system, works by forming a network in the cell nucleus, attaching chromatin to the network structure at specific sites, and orchestrating remodeling of the chromatin over long distances to regulate gene expression.

"SATB1 determines when and how the genes are read -- when they are activated and when they are repressed," says Kohwi-Shigematsu. "We have shown that SATB1 regulates gene transcription by functioning as a 'landing platform' for several chromatin remodeling enzymes, which operate within large but well defined domains."

In the 10 October 2002 issue of Nature, the researchers report that, in thymocytes, SATB1 regulates the interleukin-2 receptor-alpha gene, IL?2Ra, by bringing specific chromatin and nucleosome remodeling enzymes directly to the gene site, and by directing nucleosome positioning over 7,000 base-pairs away.

Chromatin is the complex of DNA and proteins in the nucleus of the cell. It consists of DNA wound like thread around groups of histone proteins to form bead-like nucleosomes; this string of nucleosomes is coiled into fibers 30 nanometers (billionths of a meter) thick, and the fibers are folded into chromatin loops, further compacting the DNA. Thus a eukaryotic cell can pack the entire genome of the organism, well over a meter of DNA, into a nucleus only a few millionths of a meter across.

Many orders of chromatin folding are necessary to fit the genome into a small nucleus, and this complicates the process of gene expression. For a gene to be transcribed, the double-stranded DNA that encodes it has to be unzipped -- hard to do inside tightly wound chromatin. So gene expression depends on molecular machines that rearrange the chromatin, repositioning nucleosomes along the DNA fibers.

A decade ago Kohwi-Shigematsu a
'"/>

Contact: Paul Preuss
paul_preuss@lbl.gov
510-486-6249
DOE/Lawrence Berkeley National Laboratory
9-Oct-2002


Page: 1 2 3 4

Related biology news :

1. Newly identified master gene key in babys first breath
2. Genetic master switch sends bacteria toward seafood dinner
3. Brains master molecule produces same behavior in mice from three different psychostimulant drugs
4. New approach to gene knockouts reveals the master planners of the skeleton
5. Scientists identify master molecule that controls action of many genes
6. Another job discovered for a master metabolic off-switch
7. Protein discovery tied to DNA master switch
8. School kids as master gardeners
9. DNA arrays decipher genomes master switches
10. New discovery: footprint shows master switch simultaneously controls plants disease defenses
11. New molecular link key to cellular proteins involved in cancer progression, other diseases

Post Your Comments:
(Date:5/18/2015)... , May 18, 2015 Fingerprint Cards ... FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if its ... until and including Q3 2015 and the sensors will be ... Communicated order values for 2015 hereby amount to 740 MSEK ... 2015 of 140 MSEK and a number of smaller orders ...
(Date:5/11/2015)... Curemark LLC, a privately held drug research ... Phase III double blind, randomized, placebo-controlled clinical trial to ... all children ages 3-8 with Autism. Previously, Curemark announced ... blinded clinical trial for CM-AT in children ages 3-8 ... enzyme chymotrypsin. This new trial will help determine whether ...
(Date:5/5/2015)... Conn. , May 5, 2015, NXT-ID, Inc. ... authentication company focused on the growing mobile commerce market, reminds ... Company,s Chief Technology Officer, is presenting  at CARTES SECURE CONNEXIONS ... May 5-7, 2015. The three-day conference is ... David is speaking in is themed Global Fraud: Where ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... 2015 Veolia’s environmental monitoring technology ... American distribution agreement with VWR to distribute TECTA™ ... more than 160 years of experience, VWR, a ... laboratory and production facilities, has cultivated a value ... services to enable science. Endetec’s TECTA™ B16, ...
(Date:5/20/2015)... MA (PRWEB) May 20, 2015 This ... history, especially for lawns. US Patented Pearl’s Premium ... for lawns around the country that are coming out ... that addresses a number of major global concerns related ... the “non-grass” grass – the alternative to the standard, ...
(Date:5/20/2015)... -- Health eCareers, the healthcare industry,s online career hub, ... looking for the flexibility of short-term assignments through ... tool dedicated exclusively to temporary and shift work ... employers to quickly find and hire experienced professionals ... other temporary positions, eliminating the time and resources ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 3
Cached News: